Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Subscribe To Our Newsletter & Stay Updated